<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01979601</url>
  </required_header>
  <id_info>
    <org_study_id>CLGT209X2101</org_study_id>
    <nct_id>NCT01979601</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia on Stable Doses of Statin Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to measure the effects of LGT209 when given intravenously to patients
      with high cholesterol who are on stable doses of statin medications, and to healthy subjects
      with elevated cholesterol
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>from Screening until Day 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in healthy volunteers</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in healthy volunteers</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of LGT209: : Area under the serum concentration-time curve from time zero to infinity (AUC0-inf) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2); 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of LGT209: observed maximum serum concentrations (Cmax) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of LGT209: Elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve (T1/2) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of healthy volunteers with adverse events, serious adverse events and death</measure>
    <time_frame>from Screening until Day 141</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of intravenous LGT209 in relationship to concentrations of PCSK9 and LDL-C in patients and healthy volunteers</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in patients</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>Baseline was defined as the arithmetic mean of all the pre-treatment values (i.e. Screening, Day -1 and predose on Day 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to time 't' (AUC0-t)</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
    <description>In AUC 0-t, t is a defined as time point after administration of LGT209 in patients and healthy volunteers following intravenous administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LGT209: Dose-normalized area under the serum concentration-time curve (AUC/D) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LGT209: Dose-normalized maximum serum concentrations (Cmax/D) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 ( 1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LGT209: Volume of distribution during the terminal elimination phase (Vz) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LGT209: Volume of distribution at steady state (Vss) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LGT209: Mean residence time (MRT) of LGT209 in patients and healthy volunteers following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LGT209: the systemic (or total body) clearance from serum following intravenous administration</measure>
    <time_frame>Day 1 (1, 2, 4, 6, 8, 12 hrs post dose); Post-dose at 24 hr (Day 2) 48 hr (Day 3), 96 hr (Day 5), Days 8, 11, 15, 22, 29, 43, 57, 71, 85, 113, 141</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Patient: LGT209 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient: LGT209 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg LGT209 intravenous administration in patients on stable doses of statins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient: LGT209 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg LGT209 intravenous administration in patients on stable doses of statins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient: LGT209 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg LGT209 intravenous administration in patients on stable doses of statins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient: LGT209 20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg LGT209 intravenous administration in patients on stable doses of statins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers: LGT209 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg LGT209 intravenous administration in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers: LGT209 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg LGT209 intravenous administration in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers: LGT209 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg LGT209 intravenous administration in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers: LGT209 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg LGT209 intravenous administration in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers: 20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg LGT209 intravenous administration in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching intravenous placebo in patients on stable doses of statins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching intravenous placebo in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGT209</intervention_name>
    <description>150 mg lyophilized powder in glass vial</description>
    <arm_group_label>Patient: LGT209 0.3 mg/kg</arm_group_label>
    <arm_group_label>Patient: LGT209 1 mg/kg</arm_group_label>
    <arm_group_label>Patient: LGT209 3 mg/kg</arm_group_label>
    <arm_group_label>Patient: LGT209 10 mg/kg</arm_group_label>
    <arm_group_label>Patient: LGT209 20 mg/kg</arm_group_label>
    <arm_group_label>Healthy Volunteers: LGT209 0.3 mg/kg</arm_group_label>
    <arm_group_label>Healthy Volunteers: LGT209 1 mg/kg</arm_group_label>
    <arm_group_label>Healthy Volunteers: LGT209 3 mg/kg</arm_group_label>
    <arm_group_label>Healthy Volunteers: LGT209 10 mg/kg</arm_group_label>
    <arm_group_label>Healthy Volunteers: 20 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Patient: Placebo</arm_group_label>
    <arm_group_label>Healthy Volunteers: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers: Male and female subjects 18 to 70 years of age, in general good
             health but with high cholesterol

          -  Statin patients: Male and female patients 18 to 70 years of age, with high cholesterol
             on stable statin therapy for at least 3 months

        Exclusion Criteria:

          -  Healthy volunteers: History of hypersensitivity to any of the study drugs or to drugs
             of similar chemical classes

          -  Women of child-bearing potential unless using highly effective methods of
             contraception

          -  Statin patients: Use of any prescription drugs for lipid lowering other than HMG CO-A
             reductase inhibitors (statins); use of two concurrent antihypertensive medications is
             allowed, provided stable dosing has been achieved for the prior 3 months

          -  Women of child-bearing potential unless using highly effective methods of
             contraception

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia,</keyword>
  <keyword>LGT209,</keyword>
  <keyword>PCSK9,</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

